ENTERA BIO LTD. (ENTX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 0.00 USD | Gross Profit |
| Revenue | 0.00 USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $0.00 | $0.00 | (m) | (m) |
| 2026-03-31 | $0.00 | $0.00 | (m) | (m) |
| 2025-12-31 | $0.00 | $42.00K | (m) | 0.00% |
| 2025-09-30 | $0.00 | $124.00K | (m) | 0.00% |
| 2025-06-30 | $0.00 | $166.00K | (m) | 0.00% |
| 2025-03-31 | $9.00K | $223.00K | (m) | 4.04% |
| 2024-12-31 | $9.00K | $181.00K | (m) | 4.97% |
| 2024-09-30 | $9.00K | $99.00K | (m) | 9.09% |
| 2024-06-30 | $9.00K | $57.00K | (m) | 15.79% |
| 2024-03-31 | (m) | $0.00 | (m) | (m) |
| 2023-12-31 | $0.00 | $0.00 | (m) | (m) |
| 2023-09-30 | $6.00K | $14.00K | (m) | 42.86% |
| 2023-06-30 | $8.00K | $22.00K | (m) | 36.36% |
| 2023-03-31 | $19.00K | $66.00K | (m) | 28.79% |
| 2022-12-31 | $33.00K | $134.00K | (m) | 24.63% |
| 2022-09-30 | $56.00K | $285.00K | (m) | 19.65% |
| 2022-06-30 | $129.00K | $417.00K | (m) | 30.94% |
| 2022-03-31 | $128.00K | $482.00K | (m) | 26.56% |
| 2021-12-31 | $198.00K | $571.00K | (m) | 34.68% |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | $65.00K | $365.00K | (m) | 17.81% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |